IP Library Granted Patent US 11,576,888
Granted Patent B2
US 11,576,888 · App. 16/452,189 · Granted Feb 14, 2023

Methods for treating cardiovascular diseases

Inventors: Carlo Marchetti (Denver, CO); Charles A. Dinarello (Boulder, CO)
Assignee: OLATEC THERAPEUTICS LLC
A61K31/275A61K9/0019A61K9/0053A61K9/4866A61P9/04A61P9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,576,888
App. No.
16/452,189
Granted
Feb 14, 2023
Kind
B2
Abstract

The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.

Claims (8)

1. A method of treating acute myocardial infarction (AMI) in a subject, comprising the step of:

administering to the subject suffering from AMI an effective amount of 3-methanesulfonylpropionitrile.

2. The method according to claim 1 , wherein said compound is administered by systemic administration.

3. The method according to claim 2 , wherein said compound is administered by oral administration.

4. The method according to claim 1 , wherein the treated subject has a reduction in area of damaged cardiac tissue, or infarct size.

5. The method according to claim 1 , wherein the AMI is ischemia AMI, reperfusion AMI, or non-reperfusion AMI.

6. The method according to claim 3 , wherein the subject is a human subject, and the dosage is 1-50 mg/kg/day.

7. The method according to claim 3 , wherein the subject is a human subject, and the dosage is 5-50 mg/kg/day.

Assignments (2)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2023
From: MARCHETTI, CARLO; DINARELLO, CHARLES A.
To: OLATEC THERAPEUTICS LLC
Reel/Frame 062673/0273 →
Continuity (4)
Continuation PCTUS2018012625 · Jan 5, 2018
Provisional Application 62443387 · Jan 6, 2017
Provisional Application 62506843 · May 16, 2017
Related Publication 20190307718A1 · Oct 10, 2019
Cited By (1)
US 12,582,628